|
Rosacea World Pipeline 2020 with Detailed Analysis of 21 Companies
Thursday, August 6, 2020
DUBLIN, July 29, 2020 /PRNewswire/ -- The "Rosacea Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
PIPELINE HIGHLIGHTS
Rosacea is one of the widely researched conditions during 2020 with 21 companies actively focusing on realizing pipeline's potential. Development of Rosacea medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Rosacea market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Rosacea.
Good progress is anticipated during 2020 and 2021 with Rosacea pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Rosacea pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
DRUG DEVELOPMENT PIPELINE OVERVIEW
The Rosacea pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Rosacea pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Rosacea presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Rosacea pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
DRUG PROFILES
Rosacea development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:
-- Current Status of Development including phase advancements, regulatory
approvals of phases, acquisitions, licensing and technology transfers,
product launches in various markets, and others.
-- Phase of development
-- Mechanism of Action
-- Route of Administration
-- Companies involved including originator, licensing companies, developer,
investors, and others
-- New molecular entity details
-- Orphan drug designation and other special status provided by regulators
COMPANY PROFILES
Both small size and large size pharmaceutical companies are investing their resources in Rosacea drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Rosacea. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 21 Rosacea companies including company overview, key snapshot, contact information, and their strategies on accelerating Rosacea pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Reasons to Buy
-- The current market conditions are forcing companies and investors
worldwide to prioritize their investments and accelerate pipeline
candidates only through careful quantitative assessment.
-- This research work assists decision makers in pharmaceutical companies
towards successful pipeline development through critically evaluated
pipeline data
-- Buyers can identify most promising drug candidates for treatment of
Rosacea
-- It allows users to strengthen their pipeline through acquisitions,
licensing and collaborations
-- Users can estimate possible delays in the delivery of pipeline or launch
of new products
-- Stay ahead of competition through understanding their pipeline
progression, strategies and outlook
-- The report details all the pipeline candidates under investigation in
various stages of development from Phase I through to Phase III to
enable business development managers to understand the impact of new
launches.
-- Optimize your licensing and technology transfer strategies through
identification of prospect partners
Companies Analyzed
-- Accuitis Pharmaceuticals Inc
-- Afecta Pharmaceuticals Inc
-- Aiviva BioPharma Inc
-- Alfasigma SpA
-- AOBiome LLC
-- BioMimetix JV LLC
-- Botanix Pharmaceuticals Ltd
-- Cellix Bio Pvt Ltd
-- Cutanea Life Sciences Inc
-- Dermata Therapeutics LLC
-- Dr Reddys Laboratories
-- Emeriti Pharma AB
-- Hovione
-- Maruho Co Ltd
-- Matrisys Bioscience Inc
-- Menlo Therapeutics Inc
-- Sol-Gel Technologies Ltd
-- Sunny Pharmtech Inc
-- Tarsus Pharmaceuticals Inc
-- Timber Pharmaceuticals
-- TWi Biotechnology Inc
For more information about this report visit https://www.researchandmarkets.com/r/lq7em9
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/rosacea-world-pipeline-2020-with-detailed-analysis-of-21-companies-301102184.html
SOURCE Research and Markets
|
|
|
|
Global Polymerase Chain Reaction for qPCR, dPCR, Singleplex & Multiplex Markets, 2023-2024 and 2027: Lowering Costs, Improving Outcomes and Battling Against Anti Microbial Resistance | Mar 28, 2024
|
|
Valeo Takes the Driver's Seat on Generative AI with Google Cloud | Mar 28, 2024
|
|
Second patch of "Operation Medic Bag" out now with new features and improvements | Mar 28, 2024
|
|
SS&C Unveils Next-Gen Hybrid Intelligent Automation Platform | Mar 28, 2024
|
|
Restaurantware Launches New AI-Enabled Website Design | Mar 28, 2024
|
|
MCI USA Wins Seven MUSE Creative Awards for Strategic & Digital Communications | Mar 28, 2024
|
|
Macerich Embraces Space Planning Capabilities with Yardi Floorplan Manager | Mar 28, 2024
|
|
Clarifai Named a Leader in Computer Vision Tools Report by Independent Research Firm | Mar 28, 2024
|
|
Emerson Earns 2024 ENERGY STARĀ® Partner of the Year Award for Energy Management | Mar 28, 2024
|
|
Helika Announces $50M Web3 Gaming Accelerator Program with Backing from Pantera, Spartan Capital, Sfermion & other VCs | Mar 28, 2024
|
|
|
|